Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aquestive Therapeutics, Inc.

https://aquestive.com/

Latest From Aquestive Therapeutics, Inc.

US FDA Reassures ALS Patients In Final Development Guidance

ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.

Neurology Research & Development

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • MidaSol Therapeutics LP
    • MonoSol Rx
UsernamePublicRestriction

Register